Mercaptor Wants To Reinvent Drug Discovery And Development With No Pharma Or VC Funding
Emerging Company Profile: Mercaptor – a California company that emerged from Raptor Pharmaceutical, which Horizon Pharma bought for $800m in 2016 – has grandiose plans to create a new therapy for neurodegenerative disorders with only scientists running the show and no pharma or VC backing.
You may also be interested in...
Horizon will boost its orphan drug business through the acquisition of Raptor, using a combination of debt and cash from its primary care and other assets to fund the transaction.
In the latest instalment of our VC playbook series, In Vivo sits down with Roel Bulthuis, managing partner at INKEF Capital, to discuss the group’s approach to health care investing in Europe, the importance of funding a team not just a project and how life sciences venture capital is evolving with the emergence of health tech.
Our readers have been voting and the results have been counted. The winners of In Vivo's annual Deals Of The Year contest are ...